A database of FDA approved therapeutic peptides and proteins
| This page displays user query in tabular form. |
1653 details |
| Primary information | |
|---|---|
| ThPP ID | Th1149 |
| Therapeutic Peptide/Protein Name | Ragweed Pollen Extract |
| Sequence | N.A. view full sequnce in fasta |
| Functional Classification | IIIa |
| Molecular Weight | N.A. |
| Chemical Formula | N.A. |
| Isoelectric Point | N.A. |
| Hydrophobicity | N.A. |
| Melting Point (℃) | N.A. |
| Half Life | N.A. |
| Description | Ragweed pollen extract has been developed by Curalogic. The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy. While traditional disease-modifying immunotherapeutics are administered by subcutaneous injection, Curalogic has developed a more convenient orally administered drug. |
| Indication/Disease | Investigated for use/treatment in allergic reaction. |
| Pharmacodynamics | Precise mechanism of allergen immunotherapy is not known |
| Mechanism of Action | Ragweed pollen extract is the oral immunotherapy delivered via microencapsulated beads put into a capsule, which enables the antigen to be delivered more efficiently to the Peyer's patches in the jejunum and duodenum, where the antigen can be presented and processed and not destroyed by stomach acid. |
| Toxicity | N.A. |
| Metabolism | N.A. |
| Absorption | N.A. |
| Volume of Distribution | N.A. |
| Clearance | N.A. |
| Categories | N.A. |
| Patents Number | N.A. |
| Date of Issue | N.A. |
| Date of Expiry | N.A. |
| Drug Interaction | N.A. |
| Target | N.A. |
| Information of corresponding available drug in the market | |
| Brand Name | Ragwitek |
| Company | Merck Sharp & Dohme |
| Brand Discription | Ragwitek tablets contain pollen allergen extract from Short Ragweed (Ambrosia artemisiifolia). It is a sublingual orally disintegrating tablet that dissolves rapidly. It is available as a tablet of 12 Amb a 1-U of short ragweed pollen allergen extract. |
| Prescribed for | Ragwitek is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or withoutconjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. Ragwitek is approved for use in adults 18 through 65 years of age. |
| Chemical Name | N.A. |
| Formulation | N.A. |
| Physcial Appearnce | Tablets |
| Route of Administration | Oral route |
| Recommended Dosage | One ragwitek tablet daily. |
| Contraindication | Ragwitek is contraindicated in patients with severe, unstable or uncontrolled asthma, history of any severe systemic allergic reaction, history of any severe local reaction after taking any sublingual allergen immunotherapy, history of eosinophilic esophagitis and hypersensitivity to any of the inactive ingredients [gelatin, mannitol, and sodium hydroxide] contained in this product. |
| Side Effects | Throat irritation, oralpruritus, ear pruritus, oral paraesthesia, mouth edema, and tongue pruritus. |
| Useful Link | http://www.rxlist.com/ragwitek-drug/indications-dosage.htm |
| PubMed ID | 12811019, 8760779 |
| 3-D Structure | N.A. |